Tools


Sitemap

Sitemap

Hemostasis - Webinars

26 items 1 - 15
  1. Evaluation of a New Homogeneous Immunoassay for Quantification of Prothrombin Fragment 1+2 (F1+2) in Human Plasma Samples
    2016-07-01Mattthias Ehm
    Siemens Healthineers

    Evaluation of a New Homogeneous Immunoassay for Quantification of Prothrombin Fragment 1+2 (F1+2)

    Prothrombin fragment F1+2 aids in the risk assessment of thrombosis and efficacy of anticoagulant treatment monitoring.

    • Product Lines Hemostasis
  2. Accreditation of the Medical Laboratory Image
    2015-10-01Dr. Karl-Heinz Büscher

    Accreditation of the Medical Laboratory: Opportunities and Challenges of the DIN EN ISO 15189: 2013

    Accreditation of the Medical Laboratory: Opportunities and Challenges of the DIN EN ISO 15189: 2013

    • Product Lines Hemostasis
  3. ADAMTS13, TTP, and Beyond
    2015-10-01Bernhard Lämmle
    Bern, Switzerland

    ADAMTS13, TTP, and Beyond

    ADAMTS13, TTP, and Beyond

    • Product Lines Hemostasis
  4. Diagnosing Hemophilia and Monitoring Hemostatic Therapies
    2015-10-01Steve Kitchen
    Sheffield Haemophilia Centre & UK NEQAS Blood
    Sheffield, UK

    Diagnosing Hemophilia and Monitoring Hemostatic Therapies

    Diagnosing Hemophilia and Monitoring Hemostatic Therapies

    • Product Lines Hemostasis
  5. Direct Oral Anticoagulants (DOACs): Current Indications and New Drugs in Pipeline
    2015-10-01Michael Spannagl
    Klinikum der Universität München
    Munich, Germany

    Direct Oral Anticoagulants (DOACs): Current Indications and New Drugs in Pipeline

    Direct Oral Anticoagulants (DOACs): Current Indications and New Drugs in Pipeline

    • Product Lines Hemostasis
  6. DOAC and Coagulation Testing: Facts and Artifacts
    2015-10-01Robert C. Gosselin, CLS
    UC Davis Health System
    Department of Pathology and Laboratory Medicine
    Sacramento, CA

    DOAC and Coagulation Testing: Facts and Artifacts

    DOAC and Coagulation Testing: Facts and Artifacts

    • Product Lines Hemostasis
  7. Long-acting Factor Concentrates: A New Area in Managing Hemophilia
    2015-10-01Stefan Schulte
    CSL Behring GmbH
    Behing, Germany

    Long-acting Factor Concentrates: A New Area in Managing Hemophilia

    Long-acting Factor Concentrates: A New Area in Managing Hemophilia

    • Product Lines Hemostasis
  8. NETs, Platelets, and Immunity
    2015-10-01Tobias Fuchs, PhD
    Institut für Klinische Chemie und Laboratoriumsmedizin
    Universitätsklinikum Hamburg-Eppendorf
    Hamburg, Germany

    NETs, Platelets, and Immunity

    NETs, Platelets, and Immunity

    • Product Lines Hemostasis
  9. Platelet and von Willebrand Factor Dynamics in DIC and Sepsis
    2015-10-01Bernd Jilma, MD
    Vienna, Austria

    Platelet and von Willebrand Factor Dynamics in DIC and Sepsis

    Platelet and von Willebrand Factor Dynamics in DIC and Sepsis

    • Product Lines Hemostasis
  10. Platelet Morphology and Coagulation Activation Markers Image
    2015-10-01Prof A Khalafallah
    Launceston General Hospital
    Tasmania, Australia

    Platelet Morphology and Coagulation Activation Markers: Diagnostic Utility in Hemostatic Disorders

    Platelet Morphology and Coagulation Activation Markers: Diagnostic Utility in Hemostatic Disorders

    • Product Lines Hemostasis
  11. Von Willebrand Disease and Management in 2015
    2015-10-01David Lillicrap
    Department of Pathology and Molecular Medicine
    Queen's University
    Kingston, Canada

    Von Willebrand Disease and Management in 2015

    Von Willebrand Disease and Management in 2015

    • Product Lines Hemostasis
  12. When and How to Test for DOACs in the Clinical Routine Setting
    2015-10-01Jovan P. Antovic MD, PhD
    Associate Professor - Coag Res, Dept Mol Med & Surg, KI
    Consultant - Clin Chem, Karolinska University Hospital
    Stockholm, Sweden

    When and How to Test for DOACs in the Clinical Routine Setting

    When and How to Test for DOACs in the Clinical Routine Setting

    • Product Lines Hemostasis
  13. Age-adjusted D-dimer Cutoff for Improved Efficiency in Diagnosing VTE (ADJUST-PE)
    2015-09-01Paul den Exter, MD
    Department of Thrombosis and Hemostasis
    Leiden University Medical Center
    Leiden, the Netherlands

    Age-adjusted D-dimer Cutoff for Improved Efficiency in Diagnosing VTE (ADJUST-PE)

    Age-adjusted D-dimer Cutoff for Improved Efficiency in Diagnosing VTE (ADJUST-PE)

    • Product Lines Hemostasis
  14. D-dimer in Guiding Duration of Anticoagulant Therapy (Prediction Scores, DULCIS)
    2015-03-26Gualtiero Palareti
    Cardiovascular Disease
    University of Bologna
    Bologna, Italy

    D-dimer in Guiding Duration of Anticoagulant Therapy (Prediction Scores, DULCIS)

    D-dimer in Guiding Duration of Anticoagulant Therapy (Prediction Scores, DULCIS)

    • Product Lines Hemostasis
  15. D-dimer and Stratification to Prolonged VTE Prophylaxis in Acutely Ill Patients
    2015-03-25Prof. Dr. Sebastian M. Schellong
    Dresden, Germany

    D-dimer and Stratification to Prolonged VTE Prophylaxis in Acutely Ill Patients

    D-dimer and Stratification to Prolonged VTE Prophylaxis in Acutely Ill Patients

    • Product Lines Hemostasis
26 items 1 - 15
Did this information help you ?
Thank you for your response
We detected numbers and/or an '@' symbol in your comment. Are you trying to enter a phone number or email address so that we may contact you, please contact us via our email form instead.

Note: to get a direct personal response, please contact us via our email form.

Thank you